Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand Framework.
Degtyarev E, Rufibach K, Shentu Y, Yung G, Casey M, Englert S, Liu F, Liu Y, Sailer O, Siegel J, Sun S, Tang R, Zhou J; Industry Working Group on Estimands in Oncology. Degtyarev E, et al. Stat Biopharm Res. 2020 Jul 14;12(4):427-437. doi: 10.1080/19466315.2020.1785543. Stat Biopharm Res. 2020. PMID: 34191975 Free PMC article.
Estimands for overall survival in clinical trials with treatment switching in oncology.
Manitz J, Kan-Dobrosky N, Buchner H, Casadebaig ML, Degtyarev E, Dey J, Haddad V, Jie F, Martin E, Mo M, Rufibach K, Shentu Y, Stalbovskaya V, Sammi Tang R, Yung G, Zhou J. Manitz J, et al. Among authors: degtyarev e. Pharm Stat. 2022 Jan;21(1):150-162. doi: 10.1002/pst.2158. Epub 2021 Oct 3. Pharm Stat. 2022. PMID: 34605168
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC. Kulke MH, et al. Among authors: degtyarev e. Ann Oncol. 2017 Jun 1;28(6):1309-1315. doi: 10.1093/annonc/mdx078. Ann Oncol. 2017. PMID: 28327907 Free PMC article. Clinical Trial.
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC. Pavel ME, et al. Among authors: degtyarev e. Lancet Oncol. 2017 Oct;18(10):1411-1422. doi: 10.1016/S1470-2045(17)30471-0. Epub 2017 Aug 30. Lancet Oncol. 2017. PMID: 28838862 Clinical Trial.
21 results